Ariana Pelosci

Patients with HCC who received atezolizumab/bevacizumab experienced a positive quality of life and improved disease symptoms vs sorafenib.

18FDG-PET was successful in identifying patients with HER2-positive early-stage breast cancer who were more likely to benefit from chemotherapy-free treatment with trastuzumab and pertuzumab.

The Oncologic Drugs Advisory Committee has decided to wait until more results from a clinical trial of retifanlimab are available to make a final decision about approval in squamous cell carcinoma of the anal canal.

Patients with long-term oropharyngeal cancer were surveyed regarding factors leading to severe effects on voice and speech.

STAR-OLZ has been found to significantly reduce adverse effects of chemotherapy-induced nausea and vomiting in clinical trials.

Individuals with an early-onset colorectal cancer diagnosis had a survival benefit versus those at later ages, especially for patients younger than 50 years old.

Targovax announced the FDA granted fast track designation to its investigational agent ONCOS-102 for PD-1–refractory advanced melanoma.

Bayer seeks FDA approval for its agent copanlisib in combination with rituximab for the treatment of patients with indolent non-Hodgkin lymphoma.

Differences in frequency of germline pathogenic variants were not seen in patient subsets by ethnicity when comparing 12 genes linked with breast cancer.

A trial of an eprenetapopt combination has met the prespecified primary efficacy end point in patients with acute myeloid leukemia harboring TP53 mutations.

Radioligand therapy 177Lu-PSMA-617 receives breakthrough designation from the FDA based on better overall survival outcomes in patients with metastatic castration-resistant prostate cancer.

Patients who had resection within 12 weeks of diagnosis of stage I NSCLC were found to have lower rates of recurrence.

Bemcentinib plus PD-1/L1 inhibition moves forward as therapy for patients with AXL-expressing non–small cell lung cancer.